These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 39052199

  • 21. A qualitative study to explore daily versus on-demand oral pre-exposure prophylaxis (PrEP) in young people from South Africa, Uganda and Zimbabwe.
    Dietrich JJ, Ahmed N, Tshabalala G, Wu M, Mulaudzi M, Hornschuh S, Atujuna M, Muhumuza R, Ssemata AS, Stranix-Chibanda L, Nematadzira T, Bekker LG, Martinson N, Seeley J, Fox J.
    PLoS One; 2023; 18(6):e0287627. PubMed ID: 37384792
    [Abstract] [Full Text] [Related]

  • 22. Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of Objective Measures and Self-reports of Non-adherence in ASPIRE.
    Mensch BS, Richardson BA, Husnik M, Brown ER, Kiweewa FM, Mayo AJ, Baeten JM, Palanee-Phillips T, van der Straten A, MTN-020/ASPIRE study team.
    AIDS Behav; 2019 Feb; 23(2):504-512. PubMed ID: 30218318
    [Abstract] [Full Text] [Related]

  • 23. Negative rumours about a vaginal ring for HIV-1 prevention in sub-Saharan Africa.
    Chitukuta M, Duby Z, Katz A, Nakyanzi T, Reddy K, Palanee-Phillips T, Tembo T, Etima J, Musara P, Mgodi NM, van der Straten A, MTN-020/ASPIRE Study Team.
    Cult Health Sex; 2019 Nov; 21(11):1209-1224. PubMed ID: 30657023
    [Abstract] [Full Text] [Related]

  • 24. Assessing the acceptability of, adherence to and preference for a dual prevention pill (DPP) for HIV and pregnancy prevention compared to oral pre-exposure prophylaxis (PrEP) and oral contraception taken separately: protocols for two randomised, controlled, cross-over studies in South Africa and Zimbabwe.
    Friedland BA, Mgodi NM, Palanee-Phillips T, Mathur S, Plagianos MG, Bruce IV, Lansiaux M, Murombedzi C, Musara P, Dandadzi A, Reddy K, Ndlovu N, Zulu SK, Shale LR, Zieman B, Haddad LB.
    BMJ Open; 2024 Mar 12; 14(3):e075381. PubMed ID: 38479746
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
    Glaubius R, Ding Y, Penrose KJ, Hood G, Engquist E, Mellors JW, Parikh UM, Abbas UL.
    J Int AIDS Soc; 2019 May 12; 22(5):e25282. PubMed ID: 31074936
    [Abstract] [Full Text] [Related]

  • 27. Adolescent Girls and Young Women's Experiences with Disclosing Oral PrEP or Dapivirine Vaginal Ring Use: a Multi-Country Qualitative Analysis.
    Young AM, Mancuso N, Atujuna M, Tenza S, Chitukuta M, Kemigisha D, Ngure K, van der Straten A, Garcia M, Szydlo D, Soto-Torres L, Roberts ST.
    AIDS Behav; 2023 Dec 12; 27(12):3941-3951. PubMed ID: 37392268
    [Abstract] [Full Text] [Related]

  • 28. Self-reported removal and expulsion of the dapivirine vaginal ring: qualitative reports from female ring users and their male partners in the Ring Study (IPM 027).
    Milford C, Ramlal H, Mofokeng R, Rambally Greener L, Nel A, Smit J, Malherbe M.
    BMC Public Health; 2024 May 31; 24(1):1458. PubMed ID: 38822304
    [Abstract] [Full Text] [Related]

  • 29. Experiences with simultaneous use of contraception and the vaginal ring for HIV prevention in sub-Saharan Africa.
    Leslie J, Kiweewa F, Palanee-Phillips T, Bunge K, Mhlanga F, Kamira B, Baeten J, Katz A, Hillier S, Montgomery E, MTN-020/ASPIRE Study Team.
    BMC Womens Health; 2021 Apr 23; 21(1):175. PubMed ID: 33892693
    [Abstract] [Full Text] [Related]

  • 30. "It's already in your body and it's preventing": a qualitative study of African female adolescent's acceptability and preferences for proxy HIV prevention methods in Cape Town, South Africa.
    Fynn L, Gill K, Wallace M, Atujuna M, Duyver M, Ngcobo P, Spiegel H, Rinehart A, Hosek S, Bekker LG.
    BMC Public Health; 2023 Nov 02; 23(1):2143. PubMed ID: 37919697
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Introducing the Dapivirine Vaginal Ring in Sub-Saharan Africa: What Can We Learn from Oral PrEP?
    Bhavaraju N, Shears K, Schwartz K, Mullick S, Jeckonia P, Murungu J, Persaud U, Vij A, Torjesen K.
    Curr HIV/AIDS Rep; 2021 Dec 02; 18(6):508-517. PubMed ID: 34910276
    [Abstract] [Full Text] [Related]

  • 34. Impact of Women's Home Environment on Use of the Dapivirine Vaginal Ring for HIV Prevention in Sub-Saharan Africa.
    Gichane MW, Katz AWK, Ngure K, Scheckter R, Woeber K, Reddy K, Tauya T, Zimba C, Etima J, Mangxilana N, Palanee-Phillips T, van der Straten A, MTN-025/HOPE Study Team.
    AIDS Behav; 2021 Dec 02; 25(12):3847-3857. PubMed ID: 34009480
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
    Gill K, Johnson L, Dietrich J, Myer L, Marcus R, Wallace M, Pidwell T, Mendel E, Fynn L, Jones K, Wiesner L, Slack C, Strode A, Spiegel H, Hosek S, Rooney J, Gray G, Bekker LG.
    Lancet Child Adolesc Health; 2020 Dec 02; 4(12):875-883. PubMed ID: 33222803
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.